Advanced prostate cancer (or metastatic prostate cancer) is cancer that has spread beyond the prostate gland

You may have heard the terms "metastatic castration-sensitive prostate cancer" or "metastatic castration-resistant prostate cancer"


  • In metastatic castration-sensitive prostate cancer, the disease responds to treatments that lower testosterone1
  • In metastatic castration-resistant prostate cancer, the disease keeps growing despite treatments that lower testosterone in the body1
Advanced prostate cancer
80%-90% of men with prostate cancer remain castration sensitive within 5 years of follow-up from diagnosis2

~10%-20% of men with prostate cancer progress to castration-resistant disease within 5 years of follow-up from diagnosis2

When cancer reaches this stage, it’s important to find a treatment that works well for you and helps maintain your quality of life

Understanding treatment for advanced prostate cancer

The management of advanced prostate cancer is complex and involves a variety of different treatments3-5 

Treatment can involve a wide variety of therapies, including hormone therapy, radiation therapy, chemotherapy, surgery, immunotherapy, and targeted treatments such as PARP inhibitors.1,3

The type of treatment you receive will depend on a variety of factors, including the stage and type of your prostate cancer, when you were diagnosed, and where you may be in your journey 

  • You may receive more than 1 treatment at a time1
  • Your doctor will help determine what medications or treatments are best for you1
ELIGARD® (leuprolide acetate), an androgen deprivation therapy, may be used as a foundational treatment to help lower testosterone early on and throughout your journey.6
ELIGARD® (leuprolide acetate) for injectable suspension is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer.6
ELIGARD may impair fertility in males of reproductive potential.

For Important Safety Information and full Prescribing Information for ELIGARD, visit Eligard.com.

How genetic testing plays a role

Genetic testing is important to consider when you have advanced prostate cancer. Results can tell doctors more about the type of disease you have and can help your healthcare team tailor treatments to you.1

Doctors may specifically look for a BRCA gene mutation because it can put people at higher risk of developing certain types of cancers. For women, BRCA gene mutations are common in breast cancer and ovarian cancer. For men, being positive for a BRCA gene mutation can mean you are at a higher risk of developing prostate cancer.1

PARP inhibitors like RUBRACA may be appropriate for patients with BRCA gene mutations7
Grandfather walking with granddaughter in the park.

Learn about what genetic testing may involve

BRCA, BReast CAncer gene; PARP, poly (adenosine diphosphate-ribose) polymerase.

REFERENCES: 1. Referenced with permission from the NCCN Guidelines for Patients® for Prostate Cancer: Advanced Stage. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed November 1, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. 2. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180-1192. 3. Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9. 4. Gillette CM, Yette GA, Cramer SD, Graham LS. Management of advanced prostate cancer in the precision oncology era. Cancers (Basel). 2023;15(9):2552. 5. Wahner A. OncLive. December 1, 2023. https://www.onclive.com/view/novel-combination-regimens-are-expanding-theprostate-cancer-treatment-paradigm 6. ELIGARD (leuprolide acetate). Tolmar, Inc. 2024. 7. RUBRACA (rucaparib). Prescribing Information. pharma& Schweiz GmbH. 2023.

YOU ARE NOW LEAVING RubracaProstate.com

Are you sure you want to leave?

Skip to content